Biogen Inc (NASDAQ:BIIB, XETRA:IDP) has been upgraded to ‘Buy’ from ‘Neutral’ by UBS analysts, who also raised their price target to $225 from $185, citing growing confidence in a series of clinical and commercial catalysts expected over the next 12 to 15 months.
Shares of Biogen traded hands at about $190 on Wednesday afternoon.
In a note to clients, UBS pointed to what it views as a concentrated period of pipeline readouts that could shape investor sentiment into 2027. The firm wrote that its revised outlook reflects a more constructive view on several late-stage programs across neurology, immunology, and rare disease indications.
A key near-term focus is BIIB080, an investigational tau-targeting therapy in Alzheimer’s disease, with data expected this summer. UBS noted that expectations for the readout appear relatively low and that the study size reduction may limit statistical power. Even so, the firm suggested that observed trends, such as reductions in tau pathology and potential signals on cognitive endpoints, could still be informative for the program’s development path.
Looking ahead, UBS highlighted Phase III data for litifilimab in systemic lupus erythematosus expected in the fourth quarter as a major upcoming catalyst. The firm estimates meaningful commercial potential in SLE and said positive results could support regulatory submission and further expansion into related indications.
Additional pipeline opportunities include data in cutaneous lupus erythematosus expected in 2027, which UBS described as an area with limited approved treatment options and further upside potential if earlier-stage signals are confirmed.
The note also referenced felzartamab in antibody-mediated rejection following kidney transplantation, with Phase III results anticipated in the first half of 2027. UBS described AMR as a high-need rare disease area, supported by earlier-stage clinical data.
Beyond internal programs, UBS commented on Biogen’s pending acquisition of Apellis Pharmaceuticals’ rare disease assets, describing the transaction as broadly neutral with potential modest upside. The firm wrote that the assets could contribute additional revenue streams over time and help diversify Biogen’s portfolio.
On valuation, UBS believes that Biogen trades at a discount relative to large-cap biotech peers and adjusted its earnings multiple assumption higher, reflecting its updated outlook for pipeline visibility and longer-term earnings potential.